NRGN and Alzheimer disease: Our findings suggest that patients with CAA appear to have a CSF profile distinct from both patients with AD and age-matched control participants, characterized by a global reduction in secreted AβPP and Aβ species, but normal neuronal protein levels (tau, neurogranin) compared with AD patients.